Connect with us

Hi, what are you looking for?

Jewish Business News


JPMorgan, in a rare step, recommends selling Teva shares

selling Teva shares due to concerns over the performance of the generic drug division in the United States and the company’s growing debt levels.

JPMorgan Bank today lowered Teva‘s rating (4,175.00.94% to the personal portfolio) and recommends selling Teva shares. This is due to concerns over the performance of the generic drug division in the United States and the company’s growing debt levels.

Bank analyst Chris Scott lowered Teva’s rating to a “neutral yield” from a neutral rating. Only 6% of the companies covered by JPMorgan’s analysts have such low ratings. In explaining the decision, Scott noted the challenges facing Teva’s generic drug division in the US, which he believes will not experience growth until 2019. He also mentioned the competition for Copaxone and the high level of Teva’s debt stemming from the acquisition of Actis.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.

“We see more attractive opportunities elsewhere in the sector and do not see a reason to step into TEVA shares at current levels.

While Teva’s recent appointment of Kare Schultz as President and CEO (joined Nov 1) represents a clear positive in our view, adding a highly creditable executive with significant industry experience, we do not see any quick fixes for Teva…

Overall, we believe Kare Schultz has the right background/experience set to evaluate and execute on restructuring opportunities in the Teva portfolio having successfully implementing a two-year restructuring program at Lundbeck with cost reductions exceeding expectations. However, with declining core business performance, we expect Teva’s leverage to reach >5x in 2018, limiting the new management team’s financial flexibility as it pursues a new strategic plan.”

Scott’s recommendation joins last week’s decision by the credit rating agency Fitch, which lowered Teva’s credit rating to junk. These decisions are made while the company’s share plummeted 68% since the beginning of the year and 16% in the third quarter, while the S & P 500 gained 15%.



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.

Copyright © 2021 Jewish Business News